Detalhe da pesquisa
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081848
2.
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet
; 394(10215): 2155-2164, 2019 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31813636
3.
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.
Pharmacogenet Genomics
; 28(6): 147-152, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29768301
4.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Breast Cancer Res Treat
; 168(1): 69-77, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29128898
5.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 849-56, 2016 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686957
6.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 857-65, 2016 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686960
7.
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
Ann Surg Oncol
; 24(7): 1853-1860, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27864694
8.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Lancet Oncol
; 16(9): 1037-1048, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272770
9.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24529560
10.
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
N Engl J Med
; 366(4): 310-20, 2012 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22276821
11.
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Breast Cancer Res Treat
; 153(2): 353-60, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26276354
12.
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Lancet
; 381(9880): 1827-34, 2013 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23639488
13.
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncol
; 14(12): 1183-92, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24095300
14.
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Genet Epidemiol
; 36(1): 3-16, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22161999
15.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
N Engl J Med
; 362(22): 2053-65, 2010 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-20519679
16.
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
Breast Cancer Res Treat
; 142(2): 415-21, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24202240
17.
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Lancet Oncol
; 13(7): 734-42, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22704583
18.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
J Clin Oncol
; 41(20): 3565-3575, 2023 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406456
19.
25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1.
Breast Cancer Res Treat
; 133(3): 1077-88, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22415479
20.
Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models.
Pharm Stat
; 11(5): 351-6, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22411544